The key near-term catalyst is the APPROACH Phase 3 topline readout in Q4 2026. Monitor for data release, which will determine HLP003's regulatory path and commercial viability.
Price Chart
Executive Summary
Helus Pharma provided a clinical program update via an investor presentation, reiterating that topline data from the APPROACH Phase 3 study of HLP003 for MDD is on track for Q4 2026 and announcing plans to initiate a Phase 2 monotherapy study of HLP004 for GAD in Q1 2027. No new data or financial results were disclosed; the filing is a routine pipeline update with no material change in the company's outlook.
Key Facts
- Topline data readout from APPROACH Phase 3 study of HLP003 for adjunctive MDD on track for Q4 2026.
- HLP004 Phase 2 monotherapy study for GAD expected to initiate in Q1 2027; approximately 144 participants to be randomized 1:1 to 30 mg HLP004 or placebo.
- HLP003 has FDA Breakthrough Therapy Designation; NDA filing expected in 2028.
- Enrollment of 223 participants in APPROACH Phase 3 study completed in July 2026; EMBRACE second pivotal study enrollment continuing.
- HLP004 development strategy shifted from adjunctive to monotherapy for GAD.
Financial Impact
No financial figures disclosed; clinical-stage company with no revenue.
Risk Factors
- Phase 3 topline data may fail to meet primary endpoints, significantly impairing HLP003 prospects.
- HLP004 Phase 2 monotherapy study may not demonstrate efficacy, delaying or ending the GAD program.
- Regulatory timelines (NDA filing 2028) are aspirational and subject to clinical results and FDA feedback.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001062993-26-005468 |
| Document: form6k.htm | 0001062993-26-005468 |
| Document: 0001062993-26-005468-index-headers.html | 0001062993-26-005468 |
| Document: 0001062993-26-005468-index.html | 0001062993-26-005468 |
| Document: 0001062993-26-005468.txt | 0001062993-26-005468 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.06 (−0.49%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.06 (−7.32%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.06 (−4.19%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.06 (−4.19%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.06 (−4.19%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.06 (−4.19%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.06 (−4.19%) |
Oct 15, 2026 12d ago | 6-K | $11.05 | awaiting T+20 | — | $10.06 (−8.96%) |
Oct 15, 2026 12d ago | Press Release | $11.05 | awaiting T+20 | — | $10.06 (−8.96%) |
Oct 8, 2026 19d ago | 6-K | $10.72 | awaiting T+20 | — | $10.06 (−6.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers